Ocugen Inc (OCGN)

Jul 25, 2025

Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN

Jul 25, 2025

Jul 25, 2025

CGTLive®’s Weekly Rewind – July 25, 2025 - CGTLive®

Jul 25, 2025

Jul 25, 2025

Ocugen Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

What analysts say about Ocugen Inc. stockMarket-leading profit generation - Autocar Professional

Jul 25, 2025

Jul 24, 2025

What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

What drives Ocugen Inc. stock priceStrongest growth potential - Autocar Professional

Jul 24, 2025

Jul 24, 2025

When is the best time to buy Ocugen Inc. stockMarket-leading growth rates - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®

Jul 24, 2025

Jul 23, 2025

Is Ocugen Inc. a good long term investmentSkyrocketing profit margins - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com

Jul 23, 2025

Jul 22, 2025

Ocugen announces appointments to retina scientific advisory board and executive leadership team - Ophthalmology Times

Jul 22, 2025

Jul 21, 2025

Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize

Jul 21, 2025

Jul 21, 2025

Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus

Jul 21, 2025

Jul 21, 2025

Ocugen expands advisory board and leadership team for gene therapy push - Investing.com India

Jul 21, 2025

Jul 21, 2025

Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Quiver Quantitative

Jul 21, 2025

Jul 21, 2025

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan

Jul 21, 2025

Jul 21, 2025

Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance

Jul 21, 2025

Jul 19, 2025

Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo

Jul 19, 2025

Jul 18, 2025

Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN

Jul 18, 2025

Jul 18, 2025

Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks

Jul 18, 2025

Jul 18, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus

Jul 18, 2025

Jul 18, 2025

Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia

Jul 18, 2025

Jul 18, 2025

Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa

Jul 18, 2025

Jul 18, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire

Jul 18, 2025